Palacios-Ramírez DA, Henao-Sierra JE, Arbeláez-Gómez MA, Rodelo-Ceballos JR, Arias-Restrepo LF, Bedoya-Escobar VI, Bustamante-Mira J

Language: Spanish
References: 33
Page: 57-67
PDF size: 234.08 Kb.

ABSTRACT

Introduction. Kidney transplantation is the best treatment option for patients with terminal chronic kidney disease, regardless of the etiology, making graft survival an important feature, which may be affected by immunological or non-immunological factors. This, added to the increasing number of patients on waiting lists, makes it necessary to define management strategies for these patients that allow better long-term results. Objectives. To determine the clinical, humoral and outcome characteristics in highly sensitized recipients of kidney and simultaneous kidneyliver transplant who received combined prophylaxis with intravenous immunoglobulin and plasmapheresis therapy in a Colombian medical center. Materials and methods. A retrospective, observational, descriptive study was carried out that included the transplanted patients between July 4, 2010 and April 19, 2017. Variables included the etiology of chronic kidney disease, the type of therapy received, and waiting time in days, among others. As outcomes, the presence of rejection, type of rejection, graft loss, complications and death were evaluated. Results. From a total of 25 patients, 100% received intravenous immunoglobulin and 84% plasmapheresis. Twelve percent presented graft rejection, all humoral, and 20% lost the graft. Discussion. Despite the great variety of protocols proposed in the literature, an optimal immunosuppression protocol has not been established for this particular population. The protocol in our small cohort did not have a negative impact on the percentage of post-transplant infections nor in the loss of the renal graft, but it did reduce waiting time; therefore, additional studies are required to confirm the findings in this study.

REFERENCES

1. Lopera-Medina MM. La enfermedad renal crónica en Colombia: necesidades en salud y respuesta del Sistema General de Seguridad Social en Salud. Rev Gerenc Polit Salud 2016;15:212- 233.

2. Srinivas TR, Flechner SM, Poggio ED, Askar M, Goldfarb DA, Navaneethan SD, et al. Glomerular filtration rate slopes have significantly improved among renal transplants in the United States. Transplantation 2010;90:1499-1505.

3. Gill JS, Tonelli M, Mix CH, Pereira BJ. The change in allograft function among long-term kidney transplant recipients. J Am Soc Nephrol 2003;14:1636-1642.

4. Khalkhali HR, Ghafari A. Prediction of longterm kidney failure in renal transplant with chronic allograft dysfunction using stage-specific hazard rates. Exp Clin Transplant 2012;10:8-13.

5. Opelz G, Dohler B. Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. Transplantation 2007;84:137-143.

6. Moreso F, Hernández D. ¿Ha mejorado la supervivencia del injerto tras el trasplante renal en la era de la moderna inmunosupresión? Nefrología (Madrid) 2013;33:14-26.

7. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007;18:1046-1056.

8. Gloor J, Cosio F, Lager DJ, Stegall MD. The spectrum of antibody-mediated renal allograft injury: implications for treatment. Am J Transplant 2008;8:1367-1373.

9. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, Egawa H, Yurugi K, Masuda S, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012;18:1333- 1342.

10. Askar M, Schold JD, Eghtesad B, Flechner SM, Kaplan B, Klingman L, et al. Combined liver-kidney transplants: allosensitization and recipient outcomes. Transplantation 2011;91:1286-1292.

11. Lefaucheur C, Suberbielle-Boissel C, Hill GS, Nochy D, Andrade J, Antoine C, et al. Clinical relevance of preformed HLA donor-specific antibodies in kidney transplantation. Am J Transplant 2008;8:324-331.

12. Caro-Oleas JL, Gonzalez-Escribano MF, Gentil- Govantes MA, Acevedo MJ, Gonzalez- Roncero FM, Blanco GB, et al. Clinical relevance of anti-HLA donor-specific antibodies detected by Luminex assay in the development of rejection after renal transplantation. Transplantation 2012;94:338-344.

13. Lefaucheur C, Nochy D, Hill GS, Suberbielle- Boissel C, Antoine C, Charron D, et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007;7:832-841.

14. Hidalgo LG, Campbell PM, Sis B, Einecke G, Mengel M, Chang J, et al. De novo donor-spe cific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant 2009;9:2532-2541.

15. Marfo K, Lu A, Ling M, Akalin E. Desensitization protocols and their outcome. Clin J Am Soc Nephrol 2011;6:922-936.

16. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969;280:735-739.

17. Bohmig GA, Bartel G, Wahrmann M. Antibodies, isotypes and complement in allograft rejection. Curr Opin Organ Transplant 2008;13:411-418.

18. Bos IG, Ten Berge IJ, Hack CE. Role of complement in graft rejection after organ transplantation. Transfus Med Rev 2002;16:251-264.

19. Sacks SH, Chowdhury P, Zhou W. Role of the complement system in rejection. Curr Opin Immunol 2003;15:487-492.

20. Berrón-Pérez R, Penagos-Paniagua MJ, Zaragoza-Benítez JM, Rodríguez-Álvarez J, Blancas-Galicia L. El sistema del complemento. Vías clásica y de la lectina que se une a la manosa. Alergia e Inmunol Pediatr 2003;12:46- 52.

21. Hart A, Smith JM, Skeans MA, Gustafson SK, Stewart DE, Cherikh WS, et al. OPTN/SRTR 2015 Annual Data Report: Kidney. Am J Transplant 2017;17 Suppl 1:21-116.

22. Kim IK, Vo A, Jordan SC. Transplantation in highly HLA-sensitized patients: challenges and solutions. Transplant Res Risk Manage 2014;6:99-107.

23. Bostock IC, Alberu J, Arvizu A, Hernandez- Mendez EA, De-Santiago A, Gonzalez-Tableros N, et al. Probability of deceased donor kidney transplantation based on % PRA. Transpl Immunol 2013;28:154-158.

24. Dar W, Agarwal A, Watkins C, Gebel HM, Bray RA, Kokko KE, et al. Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants. Am J Transplant 2011;11:841-847.

25. Olausson M, Mjornstedt L, Norden G, Rydberg L, Molne J, Backman L, et al. Successful combined partial auxiliary liver and kidney transplantation in highly sensitized crossmatch positive recipients. Am J Transplant 2007;7:130-136.

26. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006;6:346-351.

27. Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008;359:242-251.

28. Akalin E. Posttransplant immunosuppression in highly sensitized patients. Contrib Nephrol 2009;162:27-34.

29. Martín-Dávila P, Blanes M, Fortún J. Inmunosupresión e infección en el paciente trasplantado. Enferm Infecc Microbiol Clin 2007;25:143- 154.

30. Sethi S, Choi J, Toyoda M, Vo A, Peng A, Jordan SC. Desensitization: Overcoming the Immunologic Barriers to Transplantation. J Immunol Res 2017;2017:6804678.

31. Loupy A, Suberbielle-Boissel C, Zuber J, Anglicheau D, Timsit MO, Martinez F, et al. Combined posttransplant prophylactic IVIg/ anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation 2010;89:1403-1410.

32. Prieto F, Cabañas C, Villagra V. Características de los pacientes en espera de trasplante renal. Mem Inst Investig Cienc Salud 2015;13:49-57.

33. Vo AA, Peng A, Toyoda M, Kahwaji J, Cao K, Lai CH, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010;89:1095-1102.